Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATAI Life Sciences
Biotech
Lilly inks $2.8B AtaiBeckley psychedelic buyout to challenge J&J
Continuing its takeover spree, Lilly is moving into a psychedelic mental health sector targeted by companies including Johnson & Johnson.
Nick Paul Taylor
Jul 16, 2026 7:32am
Atai's schizophrenia drug fails to improve cognition in phase 2
Jul 28, 2025 7:45am
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Jul 1, 2025 8:30am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
2 months after depression fail, Atai lays off 30% of staff
Mar 6, 2023 11:20am
Atai drops pipeline assets, takes on debt to extend cash runway
Aug 15, 2022 7:00am
